Affinage

JAG2

Protein jagged-2 · UniProt Q9Y219

Length
1238 aa
Mass
133.4 kDa
Annotated
2026-06-10
41 papers in source corpus 25 papers cited in narrative 26 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 5/5 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

JAG2 (Jagged2) is a cell-surface Notch ligand that drives cell-fate decisions across developing epithelia, muscle, and immune compartments by activating Notch receptors on neighboring cells (PMID:16141228, PMID:16607638, PMID:39585329). In the cochlea it cooperates with DLL1 to signal through NOTCH1 and enforce lateral inhibition, restricting hair cell fate by inducing HES5 and suppressing Math1 (PMID:16141228, PMID:11545143), and analogous JAG2/NOTCH1 lateral-inhibition logic patterns oral periderm during palatogenesis (PMID:16607638) and sebocyte differentiation in skin (PMID:39585329). In muscle, cell-type-specific knockouts resolve a dual mode of action: JAG2 on muscle endothelial cells trans-activates muscle stem cell self-renewal, while JAG2 on the stem cells themselves cis-inhibits to permit differentiation, and pathogenic human JAG2 variants that fail to rescue the Drosophila ortholog cause muscular dystrophy with PAX7 and MEGF10 misregulation (PMID:33861953, PMID:42154534). JAG2 also acts as an oncogenic Notch ligand: its transcription is induced by MYC (PMID:20133585), HIF-1α under hypoxia (PMID:21402725), Wnt/β-catenin (PMID:28881809), CD146-NF-κB (PMID:40032820), and DeltaNp63 (PMID:17626181), and is epigenetically derepressed in multiple myeloma through loss of SMRT-HDAC-mediated promoter deacetylation (PMID:19417136); downstream it activates NOTCH1/NOTCH2/NOTCH3 to support tumor self-renewal, invasion, chemoresistance, and an immunosuppressive microenvironment via effects on T cells and macrophages (PMID:22341562, PMID:23211831, PMID:31619270, PMID:40120139, PMID:41916520). JAG2 surface abundance is controlled post-translationally by gamma-secretase and GSK3 (PMID:35819850) and stabilized by the deubiquitinase Usp11 (PMID:39904982); unlike its paralog JAG1, JAG2 is not cleaved by BACE1 (PMID:24907271) and lacks the NxxN motif required for NEURL-mediated activation.

Mechanistic history

Synthesis pass · year-by-year structured walk · 18 steps
  1. 2000 Medium

    Established JAG2 as a functional Notch ligand mediating lateral inhibition during sensory development, defining its core role in restricting cell fate.

    Evidence In situ hybridization comparing wild-type and Jag2 mutant cochleae with Math1/HES5 readouts

    PMID:11545143

    Open questions at the time
    • Did not identify the specific Notch receptor engaged
    • Molecular link to HES5 inferred from expression, not direct receptor activation assay
  2. 2005 High

    Resolved which receptor JAG2 signals through and the cellular basis of its phenotype, showing JAG2/DLL1 act synergistically via NOTCH1 to switch fate rather than alter proliferation.

    Evidence Genetic epistasis with Dll1/Jag2 double mutant mice and conditional Notch1 inactivation

    PMID:16141228

    Open questions at the time
    • Did not address contribution of NOTCH2/3 in other tissues
    • Mechanism of ligand cooperation not biochemically defined
  3. 2006 High

    Extended JAG2-NOTCH1 lateral inhibition to a second developmental context, palatogenesis, establishing its requirement for periderm differentiation.

    Evidence Jag2 knockout mouse analysis with recombinant explant co-culture and Notch1 activation markers

    PMID:16607638

    Open questions at the time
    • Downstream effectors of periderm differentiation not mapped
  4. 2007 Medium

    Placed JAG2 downstream of a transcription factor, DeltaNp63, in immune-organ development, beginning to define its upstream regulation.

    Evidence Genetic complementation of p63-/- mice with DeltaNp63α/TAp63α transgenes and in vivo expression analysis

    PMID:17626181

    Open questions at the time
    • Direct binding of DeltaNp63 to the JAG2 promoter not shown
    • γδ T cell defect linked correlatively
  5. 2010 Medium

    Identified JAG2 as a direct MYC transcriptional target linking oncogene activity to Notch pathway activation and tumor growth.

    Evidence Inducible Myc system, JAG2 RNAi, gamma-secretase inhibitor DAPT, and xenograft assays

    PMID:20133585

    Open questions at the time
    • Receptor identity in this context not pinned
    • Single cell-line system
  6. 2011 Medium

    Showed JAG2 is a hypoxia/HIF-1α-induced ligand with pro-angiogenic consequences, connecting the tumor microenvironment to JAG2-Notch signaling.

    Evidence HIF-1α siRNA knockdown, icN1/HEY1 readouts, JAG2 siRNA endothelial tube-formation co-culture

    PMID:21402725

    Open questions at the time
    • Direct HIF-1α binding to JAG2 promoter not demonstrated
  7. 2012 Medium

    Defined a functional requirement for JAG2 in cancer self-renewal, showing it sustains clonogenic growth of myeloma cells.

    Evidence JAG2 siRNA, NOTCH-Fc chimeric blockade, colony formation, in vivo xenograft

    PMID:22341562

    Open questions at the time
    • Receptor specificity not resolved
    • Single lab
  8. 2009 Medium

    Uncovered an epigenetic mechanism of aberrant JAG2 activation in myeloma via loss of SMRT-recruited HDAC activity at its promoter.

    Evidence Chromatin acetylation analysis, SMRT restoration, apoptosis assay

    PMID:19417136

    Open questions at the time
    • Direct SMRT occupancy at JAG2 promoter inferred
    • Single lab
  9. 2014 Medium

    Distinguished JAG2 from its paralog JAG1 at the level of protease regulation, showing JAG2 resists BACE1-mediated shedding.

    Evidence In vitro BACE1 cleavage assay comparing JAG1 vs JAG2 plus BACE1-null mouse analysis

    PMID:24907271

    Open questions at the time
    • Negative result; functional consequence of resistance not tested
    • Other shedding proteases not surveyed
  10. 2017 Medium

    Linked Wnt/β-catenin regulation of JAG2 to chemoresistance through a p21-dependent effector arm in colorectal cancer.

    Evidence β-catenin inhibitors/siRNA, APC conditional knockout, JAG2 and p21 manipulation, chemosensitivity assays

    PMID:28881809

    Open questions at the time
    • Whether p21 effect requires canonical Notch signaling unclear
  11. 2019 Medium

    Revealed both a canonical NOTCH2 anti-apoptotic/proliferative role and a non-canonical Notch-independent exosomal metastasis function for JAG2.

    Evidence Recombinant JAG2 and siRNA in nucleus pulposus cells with in vivo disc model (NOTCH2/Hes1/Hey2); separately exosome isolation and PRAF2 co-expression in CRC

    PMID:31198409 PMID:31619270

    Open questions at the time
    • Mechanism of PRAF2-dependent exosome loading not detailed
    • Non-canonical pathway receptor-independence not fully mapped
  12. 2021 Medium

    Identified JAG2 loss-of-function as a cause of human muscular dystrophy and placed it upstream of myogenic regulators including PAX7 and MEGF10.

    Evidence Whole-exome sequencing, patient muscle transcriptomics, Jag2 siRNA in myoblasts, Drosophila Serrate-Drpr genetic interaction

    PMID:33861953

    Open questions at the time
    • Cellular source of the dystrophy-relevant signal not yet resolved
    • Receptor in muscle not identified at this stage
  13. 2022 Medium

    Defined post-translational control of JAG2 surface abundance by gamma-secretase and GSK3, tuning Notch signal strength to set airway epithelial fate.

    Evidence Human air-liquid-interface cultures with gamma-secretase inhibitors, GSK3/WNT modulators, biochemical fractionation, RNA-Seq

    PMID:35819850

    Open questions at the time
    • Direct GSK3 phosphorylation site on JAG2 not mapped
  14. 2024 High

    Demonstrated ligand-specific JAG2/NOTCH1 control of sebocyte differentiation in vivo using selective antibody blockade with reversibility.

    Evidence Monoclonal antibody inhibition of individual Notch ligands/receptors in mouse skin, histology

    PMID:39585329

    Open questions at the time
    • Transcriptional program downstream in sebocytes not detailed
  15. 2024 Medium

    Established the structural/regulatory basis distinguishing JAG2 from other ligands, showing it cannot be activated by NEURL proteins due to absence of the NxxN motif.

    Evidence Humanized Drosophila rescue and mammalian Notch activation assays with motif analysis (preprint)

    Open questions at the time
    • Preprint, not peer-reviewed
    • Functional consequence of NEURL-independence in vivo not tested
  16. 2025 High

    Resolved the cell-autonomous logic of JAG2 in muscle, separating trans-activation of stem cell self-renewal from cis-inhibition of differentiation, and validated pathogenic variants as causal.

    Evidence MuEC- and MuSC-specific conditional knockout mice, co-culture, hypomorph model, Drosophila rescue with human variants

    PMID:42154534

    Open questions at the time
    • Molecular determinants of cis vs trans bias not defined
    • Receptor identity in MuSC niche not specified
  17. 2025 Medium

    Expanded JAG2's oncogenic role into immune microenvironment remodeling, showing it acts through multiple Notch receptors to generate immunosuppressive T cell and macrophage states and to support stemness.

    Evidence JAG2 neutralizing antibodies and Notch inhibitors in co-culture, xenograft, organoid and single-cell studies across eTreg (NOTCH-RBPJ), macrophage (NOTCH3-STAT3-CCL2), and CD146-NF-κB-JAG2 axes

    PMID:40032820 PMID:40120139 PMID:41916520

    Open questions at the time
    • Whether one or several receptors dominate per tumor context unclear
    • Single-lab axes await cross-validation
  18. 2025 Medium

    Added a deubiquitination layer to JAG2 regulation, with Usp11 stabilizing JAG2 to sustain marginal zone B cell survival.

    Evidence Co-immunoprecipitation, ubiquitination assay, Usp11 knockout mice, flow cytometry

    PMID:39904982

    Open questions at the time
    • Ubiquitin ligase opposing Usp11 not identified
    • Specific JAG2 ubiquitination sites not mapped

Open questions

Synthesis pass · forward-looking unresolved questions
  • It remains unresolved how the choice between JAG2 cis-inhibition and trans-activation is molecularly controlled, and which Notch receptor pairs predominate across the many tissue and tumor contexts where JAG2 acts.
  • No structural model of JAG2-receptor engagement in the corpus
  • Determinants of cis vs trans signaling undefined
  • Receptor usage in most tumor contexts not pinned down

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0048018 receptor ligand activity 4 GO:0060089 molecular transducer activity 4
Localization
GO:0005886 plasma membrane 2
Pathway
R-HSA-1266738 Developmental Biology 4 R-HSA-162582 Signal Transduction 4 R-HSA-1643685 Disease 4 R-HSA-168256 Immune System 3
Partners
DLL1NOTCH1NOTCH2NOTCH3PRAF2USP11

Evidence

Reading pass · 26 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2005 JAG2 and DLL1 act synergistically as Notch ligands to regulate hair cell differentiation in the cochlea via lateral inhibition; genetic epistasis and conditional inactivation showed both ligands signal primarily through the NOTCH1 receptor. Supernumerary hair cells in double mutants arise through cell fate switching rather than excess proliferation. Genetic epistasis (Dll1/Jag2 double mutant mice), conditional inactivation of Notch1 Development (Cambridge, England) High 16141228
2000 JAG2 (Jagged2) functions as a Notch ligand mediating lateral inhibition in cochlear development; loss of Jag2 leads to increased Math1-expressing cells and dramatically reduced HES5 expression in supporting cells, consistent with JAG2-activated Notch suppressing Math1 through HES5. In situ hybridization in wild-type vs. Jag2 mutant cochleae Journal of the Association for Research in Otolaryngology : JARO Medium 11545143
2006 JAG2 is required for Notch1 activation in oral periderm cells during palatogenesis; Jag2 mutants show significantly attenuated Notch1 activation in oral epithelium and defective periderm differentiation, causing palate-tongue fusions. Recombinant explant cultures confirmed the Jag2 mutant tongue fuses to wild-type palatal shelves. Jag2 knockout mouse analysis, molecular marker analysis, recombinant explant co-culture Developmental dynamics : an official publication of the American Association of Anatomists High 16607638
2004 JAG2 overexpression in multiple myeloma malignant plasma cells induces IL-6, VEGF, and IGF-1 secretion from stromal cells in vitro; this IL-6 induction was blocked by anti-Notch-1 monoclonal antibodies targeting the Notch-1/JAG2 binding sequence, indicating JAG2 signals through NOTCH1. JAG2 overexpression is associated with hypomethylation of its promoter. In vitro co-culture assay, neutralizing antibody blocking experiment, promoter methylation analysis Blood Medium 15292061
2009 JAG2 promoter is aberrantly acetylated in multiple myeloma due to reduced levels of the SMRT corepressor, which normally recruits HDACs to the JAG2 promoter; restoration of SMRT function induced JAG2 downregulation and MM cell apoptosis. Chromatin acetylation analysis, SMRT overexpression/restoration, apoptosis assay Cancer research Medium 19417136
2007 DeltaNp63 transcription factor enhances Jag2 expression in thymic epithelial cells in vivo; p63-/- thymi show reduced Jag2 expression and reduced γδ T cell formation similar to Jag2-/- thymi, placing JAG2 downstream of DeltaNp63 in thymic development. Genetic complementation (p63-/- mice crossed with DeltaNp63α or TAp63α transgenic mice), in vivo gene expression analysis Proceedings of the National Academy of Sciences of the United States of America Medium 17626181
2010 JAG2 is a direct transcriptional target of ectopic MYC in human B cells; JAG2 expression promotes hypoxic cell proliferation and in vivo tumorigenesis. RNAi targeting JAG2 or gamma-secretase inhibitor DAPT preferentially inhibited the neoplastic (Myc-high) state. Inducible Myc expression system (P493-6 cells), RNAi knockdown, gamma-secretase inhibitor treatment, in vivo xenograft assay Proceedings of the National Academy of Sciences of the United States of America Medium 20133585
2011 JAG2 is transcriptionally activated by hypoxia in a HIF-1α-dependent manner; hypoxic JAG2 induction increases NOTCH1 intracellular domain levels and HEY1 expression in tumor cells, and JAG2 siRNA knockdown in breast cancer cells reduces endothelial capillary tube formation in co-culture. HIF-1α siRNA knockdown, Notch target gene expression analysis (icN1, HEY1), JAG2 siRNA + endothelial co-culture tube formation assay Molecular cancer research : MCR Medium 21402725
2012 JAG2 expression is required for clonogenic (self-renewal) growth of myeloma cells; silencing JAG2 blocked colony formation in vitro and in vivo tumor formation in immunocompromised mice. Blocking JAG-NOTCH interactions with NOTCH-Fc chimeric molecules also impaired colony formation. JAG2 siRNA knockdown, NOTCH-Fc chimeric molecule blocking, colony formation assay, in vivo xenograft Blood cells, molecules & diseases Medium 22341562
2013 JAG2 promotes invasion, migration, and clonogenic growth in uveal melanoma cells; JAG2 overexpression increases Hes1 mRNA (a Notch target), and shRNA-mediated knockdown suppresses growth, invasion, and migration. JAG2 and Hes1 mRNA are enriched in invasive cells that pass through Matrigel. JAG2-GFP-MSCV overexpression, sh-JAG2 knockdown, transwell invasion/wound-healing assays, soft agar colony assay Investigative ophthalmology & visual science Medium 23211831
2014 BACE1 (β-secretase) does NOT effectively cleave JAG2, in contrast to its cleavage of JAG1, indicating selective protease-mediated regulation between these paralogs; JAG2 ectodomain shedding by BACE1 is absent despite high homology with JAG1. In vitro BACE1 cleavage assay, comparison between Jag1 and Jag2 substrates, BACE1-null mouse analysis The Journal of biological chemistry Medium 24907271
2014 JAG2 is a transcriptional target of MYC in medulloblastoma (Group 3/MYC-driven); MYC-induced transcriptional activation of JAG2 was identified as the mechanistic link between MYC oncogene activity and Notch pathway activation in MB cells. MYC knockdown/overexpression, qPCR, correlation analysis in primary tumor cohorts Acta neuropathologica communications Low 24708907
2017 JAG2 expression in colorectal cancer is regulated by Wnt/β-catenin signaling; pharmacological or genetic inhibition of β-catenin suppressed JAG2 expression, and APC deletion upregulated JAG2. JAG2 modulates chemoresistance through p21: JAG2 knockdown reduced p21, sensitizing cells to chemotherapy, and forced p21 expression rescued sensitivity; p21-null cells were unaffected by JAG2 knockdown. β-catenin inhibitors, β-catenin siRNA, APC conditional knockout mice, JAG2 knockdown/overexpression, p21 forced expression, chemosensitivity assay Oncotarget Medium 28881809
2019 JAG2 activates Notch2/Hes1/Hey2 signaling in nucleus pulposus (NP) cells to promote proliferation; this involves cyclin D1 regulation and activation of PI3K/Akt and Wnt/β-catenin pathways. JAG2/Notch2 signaling inhibits TNF-α-induced apoptosis by suppressing formation of the RIP1-FADD-caspase-8 complex. Intradiscal JAG2 injection alleviated intervertebral disc degeneration in rats. Recombinant JAG2 treatment, Notch2/Hes1/Hey2 siRNA, cell cycle analysis, PI3K/Akt and Wnt pathway assessment, apoptosis complex immunoprecipitation, in vivo rat disc injection model Arthritis research & therapy Medium 31619270
2019 JAG2 promotes migration and invasion of colorectal cancer cells through a non-canonical, Notch-independent and EMT-independent pathway. JAG2 co-expression with PRAF2 was identified; JAG2-rich exosomes are released from CRC cells in a PRAF2-dependent manner, and these exosomes promote metastasis in a paracrine fashion. siRNA knockdown, transcriptome microarray, exosome isolation and characterization, EMT pathway inhibitors, co-culture assay Cancer cell international Medium 31198409
2021 Loss-of-function JAG2 variants cause muscular dystrophy associated with misregulation of myogenesis genes including PAX7; Jag2 downregulation in murine myoblasts reduced multiple Notch pathway components including Megf10. Investigations in Drosophila revealed an interaction between Serrate (JAG1/JAG2 ortholog) and Drpr (MEGF10 ortholog), placing JAG2 upstream of MEGF10 in muscle development. Whole-exome sequencing, transcriptome analysis of patient muscle, Jag2 siRNA knockdown in murine myoblasts, Drosophila genetic interaction assay American journal of human genetics Medium 33861953
2021 MSC secretome activates the IL-6-p-STAT3-p63-JAG2 pathway in lung basal cells; inhibition of IL-6/STAT3 signaling activates p63-JAG2 signaling, promoting p63+ cell proliferation and lung repair. This pathway placement was established in a bleomycin ALI mouse model. Bleomycin ALI mouse model, intratracheal MSC supernatant lyophilized powder treatment, western blot, immunofluorescence, flow cytometry, qPCR Stem cell research & therapy Low 33781349
2022 JAG1 and JAG2 undergo posttranslational modifications in tracheobronchial epithelium: gamma-secretase complex and glycogen synthase kinase 3 are implicated in generating a JAG1 C-terminal peptide and regulating full-length JAG2 abundance on the cell surface. These distinct assemblies of JAG1 and JAG2 regulate Notch signal strength and determine cell fate (goblet vs. ciliated cells). Human air-liquid-interface cultures, gamma-secretase inhibitors, neutralizing antibodies, WNT pathway antagonists/agonists, biochemical fractionation, RNA-Seq JCI insight Medium 35819850
2024 JAG2/Notch1 is the primary signaling axis promoting sebocyte differentiation in homeostatic mouse skin; specific inhibition of JAG2 ligand (using monoclonal antibody) or Notch1 receptor causes loss of mature sebocytes and accumulation of proliferative progenitor cells. This phenotype is reversible upon removal of inhibition. Monoclonal antibody-mediated specific inhibition of individual Notch ligands/receptors in vivo (mouse), histological analysis eLife High 39585329
2024 NEURL1 and NEURL2 (Neuralized-like proteins) do NOT activate JAG2, because JAG2 lacks the Neuralized binding motif (consensus NxxN) present in DLL1 and JAG1 but absent in DLL4 and JAG2; this was demonstrated using humanized Drosophila and mammalian cell culture assays. Humanized Drosophila rescue assay, mammalian cell culture Notch activation assay, motif analysis bioRxivpreprint Medium
2025 Usp11 deubiquitinase sustains marginal zone B cell survival by deubiquitinating JAG2 (and DLL1), thereby maintaining Notch ligand levels; Usp11 knockout mice show increased MZ B cell survival after irradiation, and Co-IP/ubiquitination experiments confirmed the Usp11-JAG2 deubiquitination relationship. Co-immunoprecipitation, ubiquitination assay, Usp11 knockout mouse model, flow cytometry, immunofluorescence Cell death & disease Medium 39904982
2025 JAG2+ tumor-associated neutrophils activate Notch signaling in CD4+ T cells via RBPJ-mediated transcription, driving their differentiation into effector regulatory T cells (eTregs); this was blocked by Notch inhibitor LY3039478 or JAG2 neutralizing antibodies. JAG2-NOTCH-RBPJ axis in macrophage-adjacent T cells was demonstrated by co-culture and in vivo xenograft models. In vitro co-culture, flow cytometry, Notch inhibitor LY3039478, JAG2 neutralizing antibodies, xenograft and patient-derived tumor organoid models, scRNA-seq Cancer communications (London, England) Medium 40120139
2025 CD146 activates NF-κB signaling to upregulate JAG2 expression in hepatocellular carcinoma cells; JAG2 in turn activates Notch signaling to increase cancer stem cell stemness and chemoresistance. JAG2 overexpression rescued stemness and chemoresistance lost upon CD146 knockdown, placing JAG2 downstream of CD146-NF-κB. CD146 knockdown/overexpression, JAG2 overexpression rescue, NF-κB pathway analysis, in vitro stemness and chemoresistance assays, in vivo xenograft Cell death & disease Medium 40032820
2025 Tumor-derived JAG2 signals through macrophage NOTCH3 to induce STAT3 phosphorylation and CCL2 upregulation in macrophages, promoting an immunosuppressive M2-like/neurotrophic phenotype that facilitates perineural invasion in colorectal cancer. Disruption of JAG2-NOTCH3 signaling, STAT3 inhibition, or CCL2 blockade attenuated these effects in vitro and in vivo. Single-cell transcriptomics, ligand-receptor interaction analysis, in vitro JAG2-NOTCH3 activation assays, STAT3 inhibition, CCL2 blockade, in vivo nerve invasion model International journal of biological macromolecules Medium 41916520
2026 JAG2 deficiency impairs Notch signaling in muscle stem cells (MuSCs) and disrupts myogenic self-renewal and differentiation. In cell-type-specific conditional knockout mice: MuEC-specific Jag2 knockout reduces MuSC self-renewal (trans-activation), while MuSC-specific Jag2 knockout reduces myogenic differentiation (cis-inhibition). Human pathogenic JAG2 variants, but not reference JAG2, fail to rescue Serrate (JAG2 Drosophila ortholog) deficiency, confirming variant-specific loss of function. Cell-type-specific conditional knockout mice (MuEC- and MuSC-specific), co-culture experiments, Jag2 hypomorphic mouse model, Drosophila rescue assay with pathogenic human JAG2 variants The Journal of clinical investigation High 42154534
2018 JAG2 signaling induces CD14+ monocytes to acquire an LCH (Langerhans cell histiocytosis)-like gene signature including CD1a and langerin expression; Notch inhibition suppresses the LCH phenotype, placing JAG2-mediated Notch activation as an initiating event in monocyte-to-LCH-like cell differentiation. JAG2-stimulated monocyte differentiation assay, gene expression profiling, Notch inhibitor treatment, flow cytometry Journal of leukocyte biology Medium 30296338

Source papers

Stage 0 corpus · 41 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2005 The Notch ligands DLL1 and JAG2 act synergistically to regulate hair cell development in the mammalian inner ear. Development (Cambridge, England) 228 16141228
2004 Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines. Blood 141 15292061
2007 DeltaNp63 regulates thymic development through enhanced expression of FgfR2 and Jag2. Proceedings of the National Academy of Sciences of the United States of America 134 17626181
2000 Expression of Math1 and HES5 in the cochleae of wildtype and Jag2 mutant mice. Journal of the Association for Research in Otolaryngology : JARO 124 11545143
2006 Jag2-Notch1 signaling regulates oral epithelial differentiation and palate development. Developmental dynamics : an official publication of the American Association of Anatomists 95 16607638
2011 JAG2 induction in hypoxic tumor cells alters Notch signaling and enhances endothelial cell tube formation. Molecular cancer research : MCR 63 21402725
2009 Loss of the SMRT/NCoR2 corepressor correlates with JAG2 overexpression in multiple myeloma. Cancer research 55 19417136
2010 Induction of ectopic Myc target gene JAG2 augments hypoxic growth and tumorigenesis in a human B-cell model. Proceedings of the National Academy of Sciences of the United States of America 49 20133585
2019 JAG2/Notch2 inhibits intervertebral disc degeneration by modulating cell proliferation, apoptosis, and extracellular matrix. Arthritis research & therapy 47 31619270
2021 Lyophilized powder of mesenchymal stem cell supernatant attenuates acute lung injury through the IL-6-p-STAT3-p63-JAG2 pathway. Stem cell research & therapy 40 33781349
2014 β-site amyloid precursor protein cleaving enzyme 1(BACE1) regulates Notch signaling by controlling the cleavage of Jagged 1 (Jag1) and Jagged 2 (Jag2) proteins. The Journal of biological chemistry 33 24907271
2014 NOTCH ligands JAG1 and JAG2 as critical pro-survival factors in childhood medulloblastoma. Acta neuropathologica communications 31 24708907
2014 NOTCH1, NOTCH3, NOTCH4, and JAG2 protein levels in human endometrial cancer. Medicina (Kaunas, Lithuania) 31 25060200
2018 MicroRNA-876-3p functions as a tumor suppressor gene and correlates with cell metastasis in pancreatic adenocarcinoma via targeting JAG2. American journal of cancer research 27 29736309
2017 Jagged-2 (JAG2) enhances tumorigenicity and chemoresistance of colorectal cancer cells. Oncotarget 27 28881809
2013 A role for Jag2 in promoting uveal melanoma dissemination and growth. Investigative ophthalmology & visual science 25 23211831
2012 Critical role of the NOTCH ligand JAG2 in self-renewal of myeloma cells. Blood cells, molecules & diseases 24 22341562
2021 A form of muscular dystrophy associated with pathogenic variants in JAG2. American journal of human genetics 22 33861953
2018 JAG2 signaling induces differentiation of CD14+ monocytes into Langerhans cell histiocytosis-like cells. Journal of leukocyte biology 22 30296338
2015 A microRNA-1280/JAG2 network comprises a novel biological target in high-risk medulloblastoma. Oncotarget 20 25576913
2000 Characterization, chromosomal localization, and the complete 30-kb DNA sequence of the human Jagged2 (JAG2) gene. Genomics 16 10662552
2022 Assemblies of JAG1 and JAG2 determine tracheobronchial cell fate in mucosecretory lung disease. JCI insight 15 35819850
2025 Immunosuppressive JAG2+ tumor-associated neutrophils hamper PD-1 blockade response in ovarian cancer by mediating the differentiation of effector regulatory T cells. Cancer communications (London, England) 14 40120139
2022 miR-2392 functions as tumour suppressor and inhibits malignant progression of hepatocellular carcinoma via directly targeting JAG2. Liver international : official journal of the International Association for the Study of the Liver 14 35485355
2019 Mutual regulation of JAG2 and PRAF2 promotes migration and invasion of colorectal cancer cells uncoupled from epithelial-mesenchymal transition. Cancer cell international 14 31198409
2018 Long noncoding RNA ENST00000455974 plays an oncogenic role through up-regulating JAG2 in human DNA mismatch repair-proficient colon cancer. Biochemical and biophysical research communications 13 30473216
2019 Overexpression of JAG2 is related to poor outcomes in oral squamous cell carcinoma. Clinical and experimental dental research 12 32250571
2015 Combined QTL and selective sweep mappings with coding SNP annotation and cis-eQTL analysis revealed PARK2 and JAG2 as new candidate genes for adiposity regulation. G3 (Bethesda, Md.) 10 25653314
2022 MicroRNA-381 Regulates Proliferation and Differentiation of Caprine Skeletal Muscle Satellite Cells by Targeting PTEN and JAG2. International journal of molecular sciences 9 36362373
2025 CD146 regulates the stemness and chemoresistance of hepatocellular carcinoma via JAG2-NOTCH signaling. Cell death & disease 8 40032820
2021 An immune-related model based on INHBA, JAG2 and CCL19 to predict the prognoses of colon cancer patients. Cancer cell international 7 34103052
2024 JAG2: A Potential Biomarker for Microtia Identified by Integrated RNA Transcriptome Analysis. Current genomics 3 40433419
2025 Usp11 maintained the survival of marginal zone B cells under ionizing radiation by deubiquitinating DLL1 and JAG2. Cell death & disease 2 39904982
2024 Three novel missense variants in two families with JAG2-associated limb-girdle muscular dystrophy. Neuromuscular disorders : NMD 2 39121631
2024 The Jag2/Notch1 signaling axis promotes sebaceous gland differentiation and controls progenitor proliferation. eLife 2 39585329
2024 Case Report: Exploring the clinical spectrum of LGMD R27: insights from a case study with homozygous pathogenic variant in the JAG2 gene. Frontiers in pediatrics 1 39649397
2020 [Association between the JAG2 gene polymorphism and the occurrence of nonsyndromic cleft lip with or without cleft palate in northwest Chinese population]. Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 1 31922603
2026 Tumor-derived JAG2 programs macrophages via NOTCH3 to drive perineural invasion in colorectal cancer. International journal of biological macromolecules 0 41916520
2026 Deficiency of muscular dystrophy-related gene JAG2 causes NOTCH signaling dysfunction in muscle stem cells. The Journal of clinical investigation 0 42154534
2025 JAG2 AS A KEY MEDIATOR IN PORPHYROMONAS GINGIVALIS-INDUCED PERIODONTAL INFLAMMATION. Georgian medical news 0 40466700
2025 Low SVEP1 in intrahepatic cholangiocarcinoma mediates phenotype switching-driven metastasis by Jag2/Notch1/Hes5. Cell death & disease 0 41315239

Missed literature

Know a paper Affinage missed for JAG2? Flag it for the maintainers and the community.

No submissions yet.